Stabilization of human urine doping control samples

Analytical Biochemistry

Volumn 388, Issue 2, 2009, Pages 179-191

  Tsivou, M ^a,b   Livadara, D ^a,b   Georgakopoulos, D G ^c   Koupparis, M A ^b   Atta Politou, J ^b   Georgakopoulos, C G ^a  

^a Olympic Athletic Center of Athens   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY;

DOPING CONTROL; HUMAN URINE;

CHEMISTRY;

2,3 DEYDRO 2 DEOXY N ACETYLNEURAMINIC ACID; 4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; 4 METHOXYPHENYLSULFAMATE; AMPHOTERICIN; BOLDENONE; BORIC ACID; CHLORAMPHENICOL; CHORIONIC GONADOTROPIN; CYCLOHEXIMIDE; EDETIC ACID; ERYTHROPOIETIN; GONADOTROPIN; LUTEINIZING HORMONE; PENICILLIN DERIVATIVE; PEPSTATIN; PROTEIN; PROTEINASE INHIBITOR; SODIUM AZIDE; STEROID; STREPTOMYCIN; UNCLASSIFIED DRUG;

CANDIDA ALBICANS; CHEMICAL ANALYSIS; CONTAMINATION; DEGRADATION; DOPING; ECHOGRAPHY; ENZYME ACTIVITY; EQUIPMENT; FORENSIC MEDICINE; GEMELLA HAEMOLYSANS; GROWTH INHIBITION; HUMAN; HYDROLYSIS; LACTOBACILLUS ACIDOPHILUS; MASKING; MEDICAL SOCIETY; MEMBRANE FILTER; MICROBIAL GROWTH; MICROBIOLOGICAL EXAMINATION; MICROFLORA; MICROORGANISM; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; SPORT; STEROID BINDING; STORAGE; ULTRAVIOLET IRRADIATION; URINALYSIS; URINARY TRACT;

EID: 64249113476     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.02.016     Document Type: Review

References (130)

1. Hemmersbach P., Birkeland K.I., Norli H.R., and Ringertz S.H. Urine storage conditions and steroid profile analysis. In: Schänzer W., Geyer H., Gotzmann A., and Mareck-Engelke U. (Eds). Recent Advances in Doping Analysis vol. 4 (1997), Sport und Buch Strauß, Köln, Germany 99-106
2. Kicman A.T., Fallon J.K., Cowan D.A., Walker C., Easmon S., and Mackintosh D. Candida albicans in urine can produce testosterone: impact on the testosterone/epitestosterone sports drug test. Clin. Chem. 48 (2002) 1799-1801
3. Honour J.W. Testing for drug abuse. Lancet 348 (1996) 41-43
4. Ayotte C., Goudreault D., and Charlebois A. Testing for natural and synthetic anabolic agents in human urine. J. Chromatogr. B 687 (1996) 3-25
5. Ayotte C., Charlebois A., Lapointe S., Barriault D., and Sylvestre M. Validity of urine samples: microbial degradation. In: Schänzer W., Geyer H., Gotzmann A., and Mareck-Engelke U. (Eds). Recent Advances in Doping Analysis vol. 4 (1997), Sport und Buch Strauß, Köln, Germany 127-137
6. C. Ayotte, A. Charlebois, S. Lapointe, M. Sylvestre, D. Barriault, Microbial degradation of urine samples collected in athletic drug testing programmes, Report submitted to the International Athletic Foundation, IAF Project: 93-6, 1997.
7. van de Kerkhof D.H., de Boer D., Thijssen J.H.H., and Maes R.A.A. Evaluation of testosterone/epitestosterone ratio influential factors as determined in doping analysis. J. Anal. Toxicol. 24 (2000) 102-115
8. de la Torre R., de la Torre X., Alia C., Segura J., Baro T., and Torres-Rodriguez J.M. Changes in androgenic steroid profile due to urine contamination by microorganisms: a prospective study. Anal. Biochem. 289 (2001) 116-122
9. Geyer H., Schänzer W., Mareck-Engelke U., and Donike M. Factors influencing the steroid profile. In: Schänzer W., Geyer H., Gotzmann A., and Mareck-Engelke U. (Eds). Recent Advances in Doping Analysis vol. 3 (1995), Sport und Buch Strauß, Köln, Germany 95-113
10. Geyer H., Mareck-Engelke U., Schänzer W., and Donike M. The Cologne protocol to follow up high testosterone/epitestosterone ratios. In: Schänzer W., Geyer H., Gotzmann A., and Mareck-Engelke U. (Eds). Recent Advances in Doping Analysis vol. 4 (1996), Sport und Buch Strauß, Köln, Germany 107-125
11. Kardana A., and Cole L.A. Human chorionic gonadotropin β-subunit nicking enzymes in pregnancy and cancer patient serum. J. Clin. Endocrinol. Metab. 79 (1994) 761-767
12. O'Connor J.F., Birken S., Lustbader J.W., Krichevsky A., Chen Y., and Canfield R.E. Recent advances in the chemistry and immunochemistry of human chorionic gonadotropin: impact on clinical measurements. Endocr. Rev. 16 (1994) 650-683
13. Cole L.A. Stability of hCG free β-subunit and β-core fragment in urine. Prenat. Diagn. 17 (1997) 185-189
14. Kardana A., and Cole L.A. The stability of hCG and free β-subunit in serum samples. Prenat. Diagn. 17 (1997) 141-147
15. Muller F., Doche C., Ngo S., Faïna S., Charvin M.-A., Rebiffe M., Taguel V., and Dingeon B. Stability of the free β-subunit in routine practice for trisomy 21 maternal serum screening. Prenat. Diagn. 19 (1999) 85-88
16. Lasne F., Martin L., and de Ceaurriz J. Active urine and detection of recombinant erythropoietin. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 13 (2005), Sport und Buch Strauß, Köln, Germany 297-304
17. Belalcazar V., Gallego R.G., Llop E., Segura J., and Pascual J.A. Assessing the instability of the isoelectric focusing patterns of erythropoietin in urine. Electrophoresis 27 (2006) 4387-4395
18. Desharnais P., Groleau P.E., Hamelin C., and Ayotte C. Intermediate neuraminidase activity: a possible link toward suspicious or "effort-like" EPO isoelectric profiles. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 14 (2006), Sport und Buch Strauß, Köln, Germany 435-438
19. Maurer J., Kohler M., Schänzer W., and Thevis M. Identification of proteolytic enzymes in human urine. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 15 (2007), Sport und Buch Strauß, Köln, Germany 283-291
20. Thevis Μ., Maurer J., Kohler M., and Schänzer W. Proteases in doping control analysis. Intl. J. Sports Med. 28 (2007) 545-549
21. Dehnes Y., Borgen M., and Hemmersbach P. Enzymatic digestion of EPO. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 15 (2007), Sport und Buch Strauß, Köln, Germany 405-408
22. Lamon S., Robinson N., Sottas P.-E., Henry H., Kamber M., Mangin P., and Saugy M. Possible origin of undetectable EPO in urine samples. Clin. Chim. Acta 385 (2007) 61-66
23. Molaioni F., Abate M.G., Alocci R., Mazzarino M., Rossi F., and Botre F. Urine stability, steroid profile, T/E ratio: towards an index of sample degradation. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 13 (2005), Sport und Buch Strauß, Köln, Germany 179-188
24. Mareck U., Geyer H., Opfermann G., Thevis M., and Schänzer W. Factors influencing the steroid profile in doping control analysis. J. Mass Spectrom. 43 (2008) 877-891
25. World Anti-Doping Agency, Reporting and evaluation guidance for testosterone, epitestosterone, T/E ratio, and other endogenous steroids, WADA technical document no. TD2004EAAS. Available from: .
26. Owen R.W., Mason A.N., and Bilton R.F. The degradation of cholesterol by Pseudomonas sp. NCIB 10590 under aerobic conditions. J. Lipid Res. 24 (1983) 1500-1511
27. Owen R.W., and Bilton R.F. The biotransformation of hyodeoxycholic acid by Pseudomonas sp. NCIB 10590 under anaerobic conditions. J. Ster. Biochem. 19 (1983) 1355-1362
28. Bilton R.F. Microbial production of testosterone. Lancet 345 (1995) 1186-1187
29. Rizner T.L., Adamski J., and Zakelj-Mavric M. Expression of 17β-hydroxysteroid dehydrogenases in mesophilic and extremophilic yeast. Steroids 66 (2001) 49-54
30. 4-5β-dehydrogenase. J. Biol. Chem. 241 (1966) 906-915
31. Kjeld J.M., Puah C.M., and Joplin G.F. Rise of unconjugated sex hormones in human urine on storage. Clin. Chim. Acta 80 (1977) 285-291
32. Kwiatkowska D., Pokrywka A., Jaźwiec R., Turek-Lepa E., Starościak B., Lewandowska-Pachecka S., Pachecka J., and Grucza R. The research of microbiological stability in anti-doping samples. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 13 (2005), Sport und Buch Strauß, Köln, Germany 453-456
33. Grosse J., Rautenberg C., Wassill L., Ganghofner D., and Thieme D. Degradation of doping-relevant steroids by Rh Erythropolis. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 15 (2007), Sport und Buch Strauß, Köln, Germany 385-388
34. Kaufmann G., Thole H., Kraft R., and Atrat P. Steroid-1-dehydrogenase of Rhodococcus erythropolis. J. Steroid Biochem. Mol. Biol. 43 (1992) 297-301
35. Schänzer W., and Donike M. Metabolism of boldenone in man: gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates. Biol. Mass Spectrom. 21 (1992) 3-16
36. Schänzer W., Geyer H., Gotzmann A., Horning S., Marek-Engelke U., Nitschke R., Nolteernsting E., and Donike M. Endogenous production excretion of boldenone (17β-hydroxyandrosta-14-dien-3-one) an androgenic anabolic steroid. In: Donike M., Geyer H., Gotzmann A., and Mareck-Engelke U. (Eds). Recent Advances in Doping Analysis vol. 2 (1994), Sport und Buch Strauß, Köln, Germany p. 211
37. van der Kerkhof D.H., van der Voort P.M., de Boer D., and Maes R.A.A. Confirmation of endogenous boldenone production: a procedure for an in vivo experiment. In: Schänzer W., Geyer H., Gotzmann A., and Mareck-Engelke U. (Eds). Recent Advances in Doping Analysis vol. 17 (1999), Sport und Buch Strauß, Köln, Germany 161-168
38. Rautenberg C., Grosse J., Thieme D., Wassill L., Ganghofner D., and Mueller R.K. Testosterone degradation induced by Rh. Erythropolis. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 14 (2006), Sport und Buch Strauß, Köln, Germany 379-382
39. Piper T., Hebestreit M., Flenker U., Geyer H., and Schänzer W. A new method to determine δ13CVPDB values of trace amounts of boldenone and its main metabolite. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 15 (2007), Sport und Buch Strauß, Köln, Germany 169-178
40. Leinonen A., Apajalahti J., Moisander T., Siikanen O., Kuuranne T., and Lauraeus M. Experiments on production of "endogenous boldenone". In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 15 (2007), Sport und Buch Strauß, Köln, Germany 163-168
41. Grosse J., Anielski P., Hemmersbach P., Lund H., Mueller R.K., Rautenberg C., and Thieme D. Formation of 19-norsteroids by in situ demethylation of endogenous steroids in stored urine samples. Steroids 70 (2005) 499-506
42. Rautenberg C., Grosse J., Anielski P., Thieme D., Hemmersbach P., Lund H.S., and Mueller R.K. Aspects of in situ formation of 19-norsteroids. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 13 (2005), Sport und Buch Strauß, Köln, Germany 449-452
43. Hebestreit M., Flenker U., Fußhöller G., Geyer H., Güntner U., Mareck U., Piper T., Thevis M., Ayotte C., and Schänzer W. Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry. Analyst 131 (2006) 1021-1026
44. Stenman U.H., Unkila-Kallio L., Korhonen J., and Alfthan H. Immunoprocedures for detecting human chorionic gonadotrophin: clinical aspects and doping control. Clin. Chem. 43 (1997) 1293-1298
45. World Anti-Doping Agency, Minimum required performance levels for detection of prohibited substances, WADA technical document no. TD2009MRPL. Available from: .
46. Cole L.A. Immunoassay of human chorionic gonadotrophin, its free subunits, and metabolites. Clin. Chem. 43 (1997) 2233-2243
47. Birken S., Berger P., Bidart J.M., Weber M., Bristow A., Norman R., Sturgeon C., and Stenman U.H. Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin. Chem. 49 (2003) 144-154
48. Stenman U.H. Standardization of assays for human chorionic gonadotropin. Clin. Chem. 50 (2004) 798-800
49. Cole L.A., Sutton J.M., Higgins T.N., and Cembrowski G.S. Between-method variation in human chorionic gonadotropin test results. Clin. Chem. 50 (2004) 874-882
50. Bristow A., Berger P., Bidart J.M., Birken S., Norman R., Stenman U.H., and Sturgeon C. Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin. Chem. 51 (2005) 177-182
51. Cole L.A., Kardana A., Park S.Y., and Braunstein G.D. The deactivation of hCG by nicking and dissociation. J. Clin. Endocrinol. Metab. 76 (1993) 704-710
52. Butler S.A., Cole L.A., Chard T., and Iles R.K. Dissociation of human chorionic gonadotropin into its free subunits is dependent on naturally occurring molecular structural variation, sample matrix, and storage conditions. Ann. Clin. Biochem. 35 (1998) 754-760
53. de Medeiros S.F., Amato F., and Norman R.J. Stability of immunoreactive β-core fragment of hCG. Obstet. Gynecol. 77 (1991) 53-59
54. Kicman A.T., and Cowan D.A. Peptide hormones and sport: misuse and detection. Br. Med. Bull. 48 (1992) 496-517
55. Robinson N., Saudan C., Sottas P.-E., Mangin P., and Saugy M. Performance characteristics of two immunoassays for the measurement of urinary luteinizing hormone. J. Pharm. Biomed. Anal. 43 (2007) 270-276
56. I.Th. Papavasileiou, N.I. Legakis, Elements of General Bacteriology, second ed., Athens, Greece, 1978.
57. Lomholt J.A., and Kilian M. Immunoglobulin A1 protease activity in Gemella haemolysans. J. Clin. Microbiol. 38 (2000) 2760-2762
58. Hardman J.G., and Limbird L.E. Goodman & Gilman's The Pharmacological Basis of Therapeutics. ninth ed. (1996), McGraw-Hill, New York
59. National Formulary, National Organization for Medicines, Athens, Greece, 2003.
60. Franz M., and Hörl W.H. Common errors in diagnosis and management of urinary tract infection: I. Pathophysiology and diagnosis techniques. Nephrol. Dial. Transplant. 14 (1999) 2746-2753
61. Dart R.K. Microbiology for the Analytical Chemist (1996), Royal Society of Chemistry, Cambridge, UK
62. Muñoz P., Gijón P., Alcalà L., and Bouza E. How to manage candiduria. Rev. Med. Microbiol. 9 (1998) 225-231
63. Mackowiak P.A. The normal microbial flora. N. Engl. J. Med. 307 (1982) 83-93
64. Groh H., Schade K., and Hörhold-Schube C. Steroid metabolism with intestinal microorganisms. J. Basic Microbiol. 33 (1993) 59-72
65. Holzapfel W.H., Haberer P., Snel J., Schillinger U., and Huis in't Veld J.H.J. Overview of gut flora and probiotics. Intl. J. Food Microbiol. 41 (1998) 85-101
66. Guarner F., and Malagelada J.-R. Gut flora in health and disease. Lancet 360 (2003) 512-519
67. Nixon A., Mallet A.I., Jackman P.J.H., and Gower D.B. Testosterone metabolism by isolated human axillary Corynebacterium spp.: a gas chromatographic mass-spectrometric study. J. Steroid Biochem. Mol. Biol. 24 (1986) 887-892
68. Saudan C., Entenza J.M., Baume N., Mangin P., and Saugy M. Short-term stability of testosterone and epitestosterone conjugates in urine samples: quantification by liquid chromatography-linear ion trap mass spectrometry. J. Chromatogr. B 844 (2006) 168-174
69. Jawetz E., Melnick J., and Adelberg E. Review of Medical Microbiology. 16th ed. (1985), Lange Medical, Los Altos, CA
70. Wilson M.L., and Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin. Infect. Dis. 38 (2004) 1150-1158
71. European Urinanalysis Guidelines: Summary, Scand. J. Clin. Lab. Invest. 60 (2000) 1-96.
72. Iravani A. Advances in the understanding and treatment of urinary tract infections in young women. Urology 37 (1991) 503-511
73. Lipsky B.A. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. Ann. Intern. Med. 110 (1989) 138-150
74. McCarty J.M., Richard G., Huck W., Tucker R.M., Tosiello R.L., Shan M., Heyd A., and Echols R.M. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am. J. Med. 106 (1999) 292-299
75. Wilkie M.E., Almond M.K., and Marsh F.P. Diagnosis and management of urinary tract infection in adults. Br. Med. J. 305 (1992) 1137-1141
76. Johnson J.R., and Stamm W.E. Urinary tract infections in women: diagnosis and treatment. Ann. Intern. Med. 111 (1989) 906-917
77. Stamm W.E., and Hooton T.M. Management of urinary tract infections in adults. N. Engl. J. Med. 329 (1993) 1328-1334
78. Reynolds J.E.F. Martindale the Extra Pharmacopoeia. 31st ed. (1996), Royal Pharmaceutical Society, London
79. Stamm W.E., Hooton T.M., Johnson J.R., Johnson C., Stapleton A., Roberts P.L., Moseley S.L., and Fihn S.D. Urinary tract infections: from pathogenesis to treatment. J. Infect. Dis. 159 (1989) 400-406
80. Schwab C.J., and Straus D.C. The roles of Penicillium and Aspergillus in sick building syndrome. In: Straus D.C. (Ed). Sick Building Syndrome: Advances in Applied Microbiology vol. 55 (2004), Elsevier Academic Press, San Diego
81. Kastelic-Suhadolc T., Plemenitas A., and Zigon D. Isolation and identification of testosterone and androstenedione in the fungus Cochliobolus lunatus. Steroids 59 (1994) 357-361
82. Rao M.B., Tanksale A.M., Ghatge M.S., and Deshpande V.V. Molecular and biotechnological aspects of microbial proteases. Microbiol. Mol. Biol. Rev. 62 (1998) 597-635
83. Gupta R., Beg Q.K., and Lorenz P. Bacterial alkaline proteases: molecular approaches and industrial applications. Appl. Microbiol. Biotechnol. 59 (2002) 15-32
84. Westermeier R., and Naven T. Proteomics in Practice. A Laboratory Manual of Proteome Analysis (2002), Wiley-VCH, Weinheim, Germany
85. Siezen R.J., and Leunissen J.A.M. Subtilases: the superfamily of subtilisin-like serine proteases. Protein Sci. 6 (1998) 501-523
86. Bryan P.N. Protein engineering of subtilisin. Biochim. Biophys. Acta 1543 (2000) 203-222
87. Taussig S.J. The mechanism of the physiological action of bromelain. Med. Hypotheses 6 (1980) 99-104
88. Burrows D.L., Nicolaides A., Rice P.J., Dufforc M., Johnson D.A., and Ferslew K.E. Papain: a novel urine adulterant. J. Anal. Toxicol. 29 (2005) 275-295
89. Marciniszyn Jr. J., Hartsuck J.A., and Tang J. Mode of inhibition of acid proteases by pepstatin. J. Biol. Chem. 251 (1976) 7088-7094
90. Marcinkeviciene J., Kopcho L.M., Yang T., Copeland R.A., Glass B.M., Combs A.P., Falahatpishen N., and Thompson L. Novel inhibition of porcine pepsin by a substituted piperidine. J. Biol. Chem. 277 (2002) 28677-28682
91. Jimenez C., Ventura R., Segura J., and De la Torre R. Protocols for stability and homogeneity studies of drugs for its application to doping control. Anal. Chim. Acta 515 (2004) 323-331
92. Jimenez C., De la Torre R., Segura J., and Ventura R. Stability studies of testosterone and epitestosterone glucuronides in urine. Rapid Commun. Mass Spectrom. 20 (2006) 858-864
93. Van der Merwe P.J., and Grobbelaar E. Stability of 19-norandrosterone and 19-noretiocholanolone glucuronide in urine under various storage conditions. S. Afr. J. Sports Med. 15 (2003) 14-17
94. Van Eenoo P., Spaerkeer A., Lootens L., Van Thuyne W., Deventer K., and Delbeke F.T. Results of several (small) research projects at DoCoLab in 2005. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 14 (2006), Sport und Buch Strauß, Köln, Germany 79-85
95. Belalcazar V., Pascual J.A., Abanades S., Farré M., and de la Torre R. Stability of EPO in urine stabilized by sodium azide. In: Schänzer W., Geyer H., Gotzmann A., and Mareck U. (Eds). Recent Advances in Doping Analysis vol. 13 (2005), Sport und Buch Strauß, Köln, Germany 427-431
96. Elliott P., and Peakman T.C. The U.K. Biobank sample handling and storage protocol for the collection, processing, and archiving of human blood and urine. Intl. J. Epidemiol. 37 (2008) 234-244
97. Gika H.G., Theodoridis G.A., and Wilson I.D. Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine: sample stability under different handling and storage conditions for metabonomics studies. J. Chromatogr. A 1189 (2008) 314-322
98. Narhi L., Tsutomu A., Aoki K.H., Elmore R., Rohde M.F., Boone T., and Strickland T.W. The effect of carbohydrate on the structure and stability of erythropoietin. J. Biol. Chem. 222 (1991) 23022-23026
99. Thailkill K.M., Kumar S., Rosenberg C.K., Auten K.J., and Fowlkes J.L. Characterization of matrix metalloproteinases in human urine: alterations during adolescence. Pediatr. Nephrol. 13 (1999) 223-229
100. Lasne F., Martin L., Crepin N., and de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal. Biochem. 311 (2002) 119-126
101. Schauer-Vukasinovic V., Langen H., and Giller T. Detection of immunoreactive napsin A in human urine. Biochim. Biophys. Acta 1524 (2000) 51-56
102. Prescott L.M., Harley J.P., and Klein D.A. Microbiology. second ed. (1993), Wm. C. Brown, Dubuque, IA
103. M. Tsivou, D. Livadara, D. G. Georgakopoulos, M. Koupparis, J. Atta-Politou, C. G. Georgakopoulos, Preservation of urine doping control samples: preliminary results, in: W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck (Eds.), Recent Advances in Doping Analysis, vol. 16, Sport und Buch Strauß, Köln, Germany, 2008, pp. 41-50.
104. Gasçón J., Oubiňa A., Pérez-Lezaum A., and Urmeneta J. Sensitivity of selected bacterial species to UV radiation. Curr. Microbiol. 30 (1995) 177-182
105. Abshire R.L., and Dunton H. Resistance of selected strains of Pseudomonas aeruginosa to low-intensity ultraviolet radiation. Appl. Environ. Microbiol. 41 (1981) 1419-1423
106. Fernández R.O., and Pizarro R.A. Lethal effect in Pseudomonas aeruginosa exposed to ultraviolet-A radiation. Photochem. Photobiol. 64 (1996) 334-339
107. De Gennaro L., Cavella S., Romano R., and Masi P. The use of ultrasound in food technology: I. Inactivation of peroxidase by thermosonication. J. Food Eng. 39 (1999) 401-407
108. Ross A.I.V., Griffiths M.W., Mittal G.S., and Deeth H.C. Combining nonthermal technologies to control foodborne microorganisms. Intl. J. Food Microbiol. 89 (2003) 125-138
109. Raso J., Pagán R., Condón S., and Sala F.J. Influence of temperature and pressure on the lethality of ultrasound. Appl. Environ. Microbiol. 64 (1998) 465-471
110. Earnshaw R.G., Appleyard J., and Hurst R.M. Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound, and pressure. Intl. J. Food Microbiol. 28 (1995) 197-219
111. Ahmed F.I.K., and Russell C. Synergism between ultrasonic waves and hydrogen peroxide in the killing of micro-organisms. J. Appl. Microbiol. 39 (1975) 31-40
112. Dawson R.M.C., Elliott D.C., Elliott W.H., and Jones K.M. Data for Biochemical Research. third ed. (1998), Oxford University Press, Oxford, UK
113. Flanagan R.J., Connally G., and Evans J.M. Analytical toxicology: guidelines for sample collection postmortem. Toxicol. Rev. 24 (2005) 63-71
114. Lough P.S., and Fehn R. Efficacy of 1% sodium fluoride as a preservative in urine samples containing glucose and Candida albicans. J. Forensic Sci. 38 (1993) 266-271
115. Thierauf A., Serr A., Halter C.C., Al-Ahmad A., and Rana S. Influence of preservatives on the stability of ethyl glucuronide and ethyl sulphate in urine. Forensic Sci. Intl. 182 (2008) 41-45
116. Chang S., and Lamm S.H. Human health effects of sodium azide exposure: a literature review and analysis. Intl. J. Toxicol. 22 (2003) 175-186
117. Ventura R., Jimenez C., Segura J., and De la Torre R. Stability studies of selected doping agents in urine: caffeine. J. Chromatogr. B 795 (2003) 167-177
118. Honour J.W. Steroid profiling. Ann. Clin. Biochem. 34 (1997) 32-44
119. Padilla-Vaca F., and Anaya-Velazquez F. Biochemical properties of a neuraminidase of Trichomonas vaginalis. J. Parasitol. 83 (1997) 1001-1006
120. World Anti-Doping Agency, Harmonization of the method for the identification of epoetin alfa and beta (EPO) and darbepoetin alfa (NESP) by IEF-double blotting and chemiluminescent detection, WADA technical document no. TD2007EPO. Available from .
121. Lauer B.A., Reller L.B., and Mirrett S. Evaluation of preservative fluid for urine collected for culture. J. Clin. Microbiol. 10 (1979) 42-45
122. Gillespie T., Fewster J., and Masterton R.G. The effect of specimen processing delay on borate urine preservation. J. Clin. Pathol. 52 (1999) 95-98
123. Meers P.D., and Chow C.K. Bacteriostatic and bactericidal actions of boric acid against bacteria and fungi commonly found in urine. J. Clin. Pathol. 43 (1990) 484-487
124. Lum K.T., and Meers P.D. Boric acid converts urine into an effective bacteriostatic transport medium. J. Infect. 18 (1989) 51-58
125. Nickander K.K., Shanholtzer C.J., and Peterson L.R. Urine culture tubes: effect of sample volume on bacterial toxicity of the preservative. J. Clin. Microbiol. 15 (1982) 593-595
126. Porter L.A., and Brodie J. Boric acid preservation of urine samples. Br. Med. J. 2 (1969) 353-355
127. Watson P.G., and Duerden B.I. Laboratory assessment of physical and chemical methods of preserving urine specimens. J. Clin. Pathol. 30 (1977) 532-536
128. Fotsis T. The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS: II. Fractionation and quantitation of the main groups of estrogen conjugates. J. Steroid Biochem. 28 (1987) 215-226
129. Amies C.R., and Corpas A. A preservative for urine specimens in transit to the bacteriological laboratory. J. Med. Microbiol. 4 (1971) 362-365
130. Fayinka O.A. Boric acid: a useful preservative for urine samples. Afr. J. Med. Sci. 2 (1971) 377-385